Mylan Nifedipine Settlement Revised Certification To Paragraph III, FDA Says
Executive Summary
Mylan effectively amended its patent certification for its 30 mg extended-release nifedipine from paragraph IV to paragraph III by entering into an agreement with Pfizer to market "authorized generic" variants of Procardia XL and failing to launch its own approved version of the drug, FDA said Feb. 6.
You may also be interested in...
Generic Exclusivity Debate Continues At FDA: What Counts As A Forfeit?
FDA is continuing its case-by-case review of the 180-day exclusivity status for ANDAs as they approach marketing - most recently for generics of Bayer's Precose (acarbose), King's Altace (ramipril) and Roche's Kytril (granisetron)
Generic Exclusivity Debate Continues At FDA: What Counts As A Forfeit?
FDA is continuing its case-by-case review of the 180-day exclusivity status for ANDAs as they approach marketing - most recently for generics of Bayer's Precose (acarbose), King's Altace (ramipril) and Roche's Kytril (granisetron)
GPhA Wants “Authorized” Generics Stopped; Will FDA Help?
The Generic Pharmaceutical Association is seeking an end to the practice of "authorized" generics